Table of Contents Author Guidelines Submit a Manuscript
Journal of Osteoporosis
Volume 2013 (2013), Article ID 325693, 5 pages
http://dx.doi.org/10.1155/2013/325693
Research Article

Comparative Evaluation of Enalapril and Losartan in Pharmacological Correction of Experimental Osteoporosis and Fractures of Its Background

1Department of Traumatology and Orthopedics and Battle Field Surgery, Kursk State Medical University, Karl Marx Street, Kursk 305 004, Russia
2Department of Clinical Pharmacology, Kursk State Medical University, Karl Marx Street, Kursk 305 004, Russia
3Department of Pharmacology, Kursk State Medical University, Karl Marx Street, Kursk 305 004, Russia
4Department of Histology, Cytology and Embryology, Kursk State Medical University, Karl Marx Street, Kursk 305 004, Russia

Received 30 September 2012; Revised 1 December 2012; Accepted 19 December 2012

Academic Editor: Jun Iwamoto

Copyright © 2013 D. S. R. Rajkumar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. L. Nasonov, “Secondary osteoporosis: pathogenesis and clinical significance in inflammatory diseases of joints,” Osteoporosis and Osteopathy, vol. 3, pp. 18–20, 1998. View at Google Scholar
  2. K. Alagiakrishnan, A. Juby, D. Hanley, W. Tymchak, and A. Sclater, “Role of vascular factors in osteoporosis,” Journals of Gerontology, vol. 58, no. 4, pp. 362–366, 2003. View at Google Scholar · View at Scopus
  3. V. V. Brooches, “Nitric oxide as a regulator of protective and homeostatic reactions of organism,” Brooches.V.V/Ukraine Revmatol journal, vol. 4, pp. 3–11, 2003. View at Google Scholar
  4. C. Napoli and L. J. Ignarro, “Nitric oxide and atherosclerosis,” Nitric Oxide, vol. 5, no. 2, pp. 88–97, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Stimpel, W. S. S. Jee, Y. Ma, N. Yamamoto, and Y. Chen, “Impact of antihypertensive therapy on postmenopausal osteoporosis: Effects of the angiotensin converting enzyme inhibitor moexipril, 17β-estradiol and their combination on the ovariectomy-induced cancellous bone loss in young rats,” Journal of Hypertension, vol. 13, no. 12, pp. 1852–1856, 1995. View at Google Scholar · View at Scopus
  6. J. B. Laursen, S. Rajagopalan, Z. Galis, M. Tarpey, B. A. Freeman, and D. G. Harrison, “Role of superoxide in angiotensin II-induced but not catecholamine- induced hypertension,” Circulation, vol. 95, no. 3, pp. 588–593, 1997. View at Google Scholar · View at Scopus
  7. M. E. Galagan, A. V. Shirokolova, and A. F. Vanin, “Hypertensive action of the nitric oxide produced by of exogenous and endogenous sources,” Voprosy Meditsinskoi Khimii, vol. 37, no. 1, pp. 67–70, 1991. View at Google Scholar
  8. M. V. Korokin, A. M. Nosov, and M. V. Pokrovskii, “A comparative study of endothelium-cardioprotective properties of furastanol glycosides from the cell culture plant Dioscorea cleltoidea and 17β-estradiol,” Kuban Scientific Medical Bulletine, vol. 9, no. 90, pp. 137–140, 2006. View at Google Scholar
  9. M. V. Pokrovskii, O. S. Gudyrev, A. V. Faitelson, G. M. Dubrovin, and E. B. Artyushkova, “Method for correction of osteoporosis and the prevention of osteoporotic fractures enalapril,” no. 2369390, Bulletine 28, 2009.
  10. M. V. Pokrovskii, O. S. Gudyrev, A. V. Faitelson et al., “Patent=RF. Method for correction of osteoporosis and the prevention of osteoporotic fractures losartan,” no. 2369391, Bulletine 28, 2009.